Global X Lithium & Battery Tech ETF vs 10X Genomics Inc — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.73 (market cap $1.45B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 6.9× Global X Lithium & Battery Tech ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 56 Days and 10X Genomics Inc for 91 Days on average.
| LIT | TXG | |
|---|---|---|
Market Cap | $1.45B | $10.07B |
Volume | 89,392 | 5,657,286 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $97.74 |
52-Week Low | $53.92 | $11.48 |
Typical Hold Time | 56 Days | 91 Days |
Enterprise Value | — | $9.59B |
Signals from Pluang's Aura AI — not financial advice
LIT (Global X Lithium & Battery Tech ETF) trades at $69.02, down 0.7% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF's recent performance reflects ongoing volatility in lithium markets, with short interest dropping 53.1% in September 2026. Recent news highlights continued growth in electric vehicle adoption and China's ambitious 30% NEV fleet target by 2030, supporting long-term battery technology demand.
The ETF presents exposure to the growing battery technology sector with strong catalysts from EV adoption and energy storage markets. However, investors face risks from lithium price volatility, Chinese export controls on critical minerals, and geopolitical trade tensions that could impact supply chains and performance.
TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.
The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →